{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:35:04Z","timestamp":1787960104346,"version":"build-2784847793"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014713","name":"ARC Training Centre in Lightweight Automotive Structures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jgar.2021.04.020","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T12:41:05Z","timestamp":1621428065000},"page":"4-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["In vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin infections"],"prefix":"10.1016","volume":"26","author":[{"given":"Denis","family":"Pi\u00e9rard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.04.020_bib0001","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.2147\/IDR.S172366","article-title":"Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics","volume":"11","author":"Leong","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2021.04.020_bib0002","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12879-015-0822-2","article-title":"Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study","volume":"15","author":"Garau","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2021.04.020_bib0003","first-page":"iii35","article-title":"Complicated skin and soft tissue infection","volume":"65","author":"Dryden","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.04.020_bib0004","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2021.04.020_bib0005","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1093\/ofid\/ofy270","article-title":"Twenty-year trends in antimicrobial susceptibilities among Staphylococcus aureus from the SENTRY antimicrobial surveillance program","volume":"6","author":"Diekema","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.020_bib0006","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.diagmicrobio.2014.01.003","article-title":"Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010\u20132012)","volume":"78","author":"Flamm","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.020_bib0007","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.diagmicrobio.2016.07.012","article-title":"In vitro activity of ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012\u20132014","volume":"86","author":"Karlowsky","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.020_bib0008","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jac\/dkv311","article-title":"In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme","volume":"71","author":"Karlowsky","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.04.020_bib0009","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/jac\/dkp503","article-title":"Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae","volume":"65","author":"Moisan","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.04.020_bib0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2147\/TCRM.S75412","article-title":"Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia","volume":"11","author":"Mpenge","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jgar.2021.04.020_bib0011","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1128\/AAC.00019-10","article-title":"Affinity of ceftaroline and other \u03b2-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae","volume":"54","author":"Kosowska-Shick","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.020_bib0012","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1128\/AAC.03622-14","article-title":"PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates","volume":"58","author":"Long","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.020_bib0013","unstructured":"European Medicines Agency. Zinforo: European public assessment report (EPAR) \u2013 product Information.EMEA\/H\/C\/002252. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zinforo-epar-product-information_en.pdf [accessed 29 April 2020]."},{"key":"10.1016\/j.jgar.2021.04.020_bib0014","unstructured":"TEFLARO\u00ae prescribing information. https:\/\/www.allergan.com\/assets\/pdf\/teflaro_pi [accessed 10 February 2020]."},{"key":"10.1016\/j.jgar.2021.04.020_bib0015","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2018"},{"key":"10.1016\/j.jgar.2021.04.020_bib0016","series-title":"Breakpoint tables for interpretation of MICs and zone diameters","year":"2020"},{"key":"10.1016\/j.jgar.2021.04.020_bib0017","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/AAC.05186-14","article-title":"Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009\u20132013","volume":"59","author":"Lob","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.020_bib0018","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.020_bib0019","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2020"},{"key":"10.1016\/j.jgar.2021.04.020_bib0020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.diagmicrobio.2018.09.002","article-title":"Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015\u20132016 from North America and Europe","volume":"93","author":"Huang","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.020_bib0021","first-page":"e01715","article-title":"In vitro activity of eravacycline against Gram-positive bacteria isolated in clinical laboratories worldwide from 2013\u20132017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.020_bib0022","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bjid.2017.03.010","article-title":"In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid","volume":"21","author":"Vanegas M\u00fanera","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.020_bib0023","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.diagmicrobio.2006.05.009","article-title":"Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998\u20132004)","volume":"57","author":"Moet","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.020_bib0024","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s15010-008-3408-8","article-title":"Complicated skin and soft-tissue infections\u2014consider Gram-negative pathogens","volume":"36","author":"Ruef","year":"2008","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2021.04.020_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.05.015","article-title":"Activity of ceftaroline against pathogens associated with community-acquired pneumonia collected as part of the AWARE surveillance program, 2015\u20132016","volume":"95","author":"Bae","year":"2019","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521001193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521001193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:56:16Z","timestamp":1761990976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521001193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":25,"alternative-id":["S2213716521001193"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.04.020","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin infections","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021. Pfizer Inc. and the Author(s). Published by Elsevier.","name":"copyright","label":"Copyright"}]}}